FDA Moves On Novartis Gene Therapy May Be Good For Kite Pharma – Barron’s
Barron’s |
FDA Moves On Novartis Gene Therapy May Be Good For Kite Pharma
Barron’s A Food And Drug Administration panel is expected to meet tomorrow to discuss Novartis’s (NVS) experimental gene therapy drug, a move that could be good news for Kite Pharma (KITE), according to Canaccord Genuity. Illustration: Getty Images/iStockphoto. |
|
Novartis’ CAR-T Therapy for Pediatric Leukemia to Face FDA Advisory Panel
AJMC.com Managed Markets Network Novartis’ chimeric antigen receptor T-cell (CAR-T) therapy for treating pediatric leukemia is on the cusp of being the first FDA-approved gene therapy, which will lead to new developments and utilizations of CAR-T therapy for treating other advanced … |
Life Sciences Intellectual Property Review (subscription) |
Broad Institute enters talks for CRISPR licensing pool
Life Sciences Intellectual Property Review (subscription) The Broad Institute of MIT and Harvard has announced that it has entered talks to create a worldwide licensing pool for CRISPR/Cas9 patents. In a statement released on Monday, July 10, the Broad said it hoped a patent pool would create a “one-stop shop … |
|
Synthetic Biology Advance May Put Microbiomes on the Clock
Genetic Engineering & Biotechnology News This master clock works by combining synthetic biology circuits that can dynamically increase and decrease DNA copy number and thereby turn gene expression up and down. Until now, methods for controlling or programming bacterial cells involved … |
|
Benefits of using Droplet Digital PCR for measuring immunotherapy response highlighted in presentations at 2017 …
EurekAlert (press release) July 11, 2017 — New research demonstrating the clinical potential of Bio-Rad’s Droplet Digital PCR (ddPCR) technology to measure patient response to immunotherapy was presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in … |